




ISSN : 2347-2251

**Indo-American Journal of
Pharma and Bio Sciences**



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



REGULATORY OPERATIONS IN RARE DISEASES: CHALLENGES AND STRATEGIES FOR GLOBAL SUBMISSIONS

Author Name: Sharath Reddy Venna

Role: Senior Manager Regulatory Operations/Informatics

Affiliation: Leadiant Biosciences, USA

Email: vennasharath@gmail.com

Abstract: *This research aims to “analyse the challenges associated with regulatory operations in rare diseases and propose strategies for efficient global submissions”. “Rare diseases regulatory operations” require traversing specialised pathways and regulations in efforts to facilitate the advancement and approval of treatments. Both secondary qualitative and quantitative methods were selected to analyse “regulatory operations in rare diseases.” Case study examples, including Novartis, JCR Pharmaceuticals, and Marathon Pharmaceuticals, were included, along with a statistical overview of “rare diseases.” Findings revealed thriving proportions of “rare disease,” and many countries have Orphan Drug designation, which gives such incentives to the medical companies to grow drugs for rare diseases, such as financial benefits, tax breaks, and potentially faster regulatory review.*

Index terms: *Regulatory Operations, Rare Diseases, Orphan Drug, FDA*

I. INTRODUCTION

A. Background to the Study

Rare diseases encompass many conditions that affect a small fraction for people who live with a disease every day. Clinical trials have limited recruitment, data collection and establishing efficacy due to the few patients [1]. The fact that there are no harmonised regulatory rules globally also complicates global submissions. Special pathways have been presented by “regulatory agencies, including the Food and Drug Administration

(FDA), European medicines agencies (EMA), and Pharmaceuticals and Medical Devices agencies (PMDA)”, as orphan drug designations, fast track approval and adaptive licensing, etc., to encourage development. But this documentation, submission timelines, and compliance standards are all different from regulatory requirement to requirement and are very complex for innovative treatment access in the global markets.

B. Overview

Strategic planning for regulators in rare diseases is required and should be in line with international regulations and health authorities. Companies having to develop new treatments operate in environments where they need to operate in a highly networked environment and within various regulatory frameworks and also address the scientific and ethical considerations in the design of the trials. Complexity has also increased further as much needs to be differentiated on data expectation, country specific requirement and post market surveillance obligations [2]. Among other challenges, high costs, variable approval timelines in some cases, and inconsistencies in patient access to new therapies, are included. Strategies for overcoming these hurdles and expediting the process of global submissions involve strategic planning for regulatory submissions, interacting with regulatory agencies and using real world evidence (RWE).



C. Problem Statement

The medical organisations have struggle to done their treatments over rare disease. Moreover, uncertainties remain in the efficacy and safety of effectiveness assessment due to the small patient populations in clinical trials [3]. These challenges need to be addressed with an integrated work of a governing strategy that goes beyond compliance for efficiency, for a speedy patient access to innovative treatments throughout the world.

D. Objectives

The main goals of this project are: 1. To inspect the regulatory pathways which is available for rare disease treatments across major global agencies. 2. To identify some key challenges faced by pharmaceutical companies in the submission process got orphan drugs. 3. To explore some new strategies for optimising regulatory submission to achieve faster global market approval. 4. To assess the role of real-world evidence and adaptive regulatory approaches in facilitating rare disease drug approvals. These objectives aim to analyse the challenges associated with regulatory operations in rare disease and propose strategies for effective global submissions.

E. Scope and Significance

The scope of the study focuses on regulatory requirements of rare disease treatments in key markets of the USA, Europe and Japan [4]. This highlights the differences in the approval process and evaluates the strategies to enhance regulatory effectiveness. The significance of findings for pharmaceutical companies, policy makers and healthcare professionals is to improve patient access to life-saving therapies.

II. LITERATURE REVIEW

A. Global Regulatory Pathways for Rare Disease Treatments

Rare diseases collectively exert a global public health burden in the severity of their manifestations and the total number of people they afflict. As for multiple patients, considerable barriers exist in terms of access to appropriate care, delayed diagnosis and limited or non-existing treatment options. The study explores the US Orphan Drug Act of 1983, which served as a most important act which consists of milestones by giving a roadmap for other countries to introduce and implement similar orphan drug legislation [5]. EU also follow this process to encourage the widespread adoption and implementation of rare disease plans or strategies to design more accurate and comprehensive needs of patients with rare diseases.

The study is focused on the interest of patients, industry, and regulatory groups to rigorously and transparently integrate patient-voice into regulatory decision-making. "Patient-focused drug development (PFDD)" is an approach that is used in the study to systematically incorporate patient experiences into drug development and evaluation [6]. The study also explores the nature of advocacy-regulatory relations that precede PFDD, characterises current PFDD and other patient-engagement activities, and explores opportunities for future patient participation in drug development, which has been looked at by the regulatory bodies in different countries, such as the FDA and EMA.



B. Challenges in Orphan Drug Submissions




Figure 1: Number of orphan product designations and approvals

[7]

The pathophysiology of common diseases is now better understood, in large part due to research on unusual disorders. However, due to their tiny numbers and lack of profitability, the pharmaceutical industry and society have historically ignored the medical requirements of individuals with rare diseases. The first significant effort to address the unmet medical needs of people with rare diseases and to encourage the pharmaceutical sector to support orphan medication development was the “Orphan Drug Act of 1983” [7]. The process of drug development in rare diseases is no different from that for common diseases and also involves significant infrastructure and cost. In the year 2016, the number of orphan product designations was 333, which was less than in comparison with the year 2015, which had 354 [7].

The Regulation on Orphan Medicinal Products’ success in the “European Union” is evidenced by the 127 orphan drugs that have had authorisation of market since 2000 [8]. The regulatory bodies aim to stimulate research and development, which has had the unintended consequence of increasing drug cost and this is one of the challenges that need to be mitigated by the EU by implementing

the regulatory of EMA. In supporting and motivating non-profit organizations to take the lead in the development of reasonably priced orphan pharmaceuticals, this narrative review uses repurposed drugs as a model to overcome regulatory obstacles, explain the legal environment, and identify financing options.

C. Optimizing Regulatory Submissions for Faster Market Approval

The study is focused on enhancing market access to rare diseases by optimising regulatory submissions by launching new therapies for rare diseases, implying the ability for the manufacturer to achieve a level of reimbursed price and a level of market access that are commercially viable on multiple markets [9]. Accessing of new therapies are challenging for some of countries due to regulatory issues and funding is also insufficient to make it challenging in some of the countries around the globe. However, the industry has some opportunities to partner with the healthcare system to identify and address the issue. This issue can be mitigated through evidence-based pricing and innovative contracting.

D. Leveraging Real-World Evidence and Adaptive Approaches

Leveraging “Real-World Evidence (RWE)” in rare diseases drug development is the path to different regulatory approval and different market access for the rare disease therapies presents unique challenges. With the low number of patient population and heterogenous data, the development of “therapeutics” for rare diseases requires a different, innovative, and creative approach [10]. This approach can be derived from the multiple clinical approaches that can be used in routine patient care data that complements the clinical trials by giving different insights that can be effective. This also follows the regulatory measures such as FDA or EMA, which can be safe and real-world use of



medical products which going beyond the controlled environment of trials.

III. METHODOLOGY

A. Research Design

A research design acts as a strategy to answer research questions with the help of empirical data. “Descriptive, exploratory, and explanatory” are three types of research design, and “*explanatory research design*” is selected here to analyse “regulatory operations in rare diseases.” “Explanatory research design” is a two-stage which includes quantitative measurements being used as the basis on which to create and describe qualitative information [11]. Therefore, this has been selected as it initiates transparency in the correlation between cause and effect, highlights regulatory threats, and cultivates initiatives related to the global submission. Descriptive and exploratory research designs were not selected because of the lack of causal evaluations. Moreover, explanatory research design specifies a structured context, coordinating authoritative challenges to strategic interventions effectively.

B. Data Collection

This research has incorporated a multi-research method, including both secondary quantitative and qualitative data collection and analysis strategies. Data sources used for the qualitative research are academic journal articles, case study examples, industry reports, and others. After that, statistical charts, graphs, and metrics are gathered and further analysed in a secondary quantitative method.

C. Case Studies/Examples

Case Study 1: Zolgensma for SMA - Spinal Muscular Atrophy

Zolgensma has been identified as a gene therapy created by the company Novartis for core SMA that hampers the functions of human muscles. This was acknowledged by the FDA in year of 2019, and Zolgensma

observed authoritative threats because of its novel gene-cure context and initial high prices [12]. Thus, this method depends on non-comparative investigations and “2 open-label” processes showing the recruitment for strong measures in the orphan drug trials and approvals.

Case Study 2: Pabinafusp-Alfa for Mucopolysaccharidosis Type II in Brazil

JCR Pharmaceuticals has launched “pabinafusp-alfa” as an alternative option for “Hunter syndrome.” Patient organisations in countries like Brazil have been helping to secure initial access before getting acknowledgement from the regulators. 20 patients in 2020 were treated under this standard cost-effectively while developing their outcomes and expectations [13].

Case Study 3: Deflazacort for Duchenne Muscular Dystrophy

Marathon Pharmaceuticals got approval from the end of FDA regarding Emflaza as a treatment for DMD, “Duchenne Muscular Dystrophy.” Apart from the availability and accessibility of the drug at a lower price point in other regions, the high pricing of the company creates controversies in the United States [14]. Marathon Pharmaceuticals sold their stakes to “PTC Therapeutics,” and this example demonstrates ethical dilemmas in the drug pricing for rare cases.

D. Evaluation Metrics

Evaluation metrics in this regard include “patient access rates,” “time of approval,” “cost,” and “success rates of clinical trials.” Critical inequities are present concerning patient access for diseases [15]. These metrics cultivate the integration of regulatory initiatives, facilitate submissions globally, specify the cost-effectiveness of the treatment, and maintain safety protocols. These have been improving coordination with the stakeholders and strengthening access to long-term treatments.



IV. RESULTS

A. Data Presentation

Regulatory operations in terms of rare diseases face several hurdles, including their cost structure, limited information on trials, and a complex process to get the approval. Initiatives for its worldwide submission involve leveraging real-world data, initial engagement and flexible design of the trial phase along with the authoritative bodies.




Figure 2: Overall market share of ODs
[16]

In the “general population”, the proportion of “pharmaceutical expenditures” for ODs rose from 0.4% in 2010 to 3.2% in 2020 [16]. The “percentage of ODs” in children ages 0–12 rose from 1.2% in 2010 to 6.2% in 2020, while the percentage in teenagers ages 13–17 climbed from 2.1% in 2010 to 11.2% in 2020 [16].




Figure 3: Global prescription orphan drug sales from 2016 to 2028
[17]

This figure displays the global revenue from 2016 to 2028 from prescription orphan medications. Revenues from orphan pharmaceuticals reached 132 billion dollars in 2020 [17]. Rare diseases or disorders defined in the US as affecting fewer than 200,000 patients are the focus of orphan medications [17].




Figure 4: Orphan Drug Sales and Share of Total Sales
[18]

Though the number of approved orphan drugs rose from 364 in 2013 to 487 in 2017, the share of total spending attributed to orphan indication use rose from 8.1% to 9.6%, from about 3% in 1993 [18]. 15.3% of total medicines spending is non-orphan use of these molecules, suggesting that these molecules are able to obtain sales and sales of most of their molecules with both orphan and non-orphan indications, the amount of their use and sales for the non-orphan indications is much larger than the orphan indication [18].

B. Findings

Coordinating global standards and advocacy of the patients are pivotal in accelerating approvals while specifying efficacy and safety to cure rare “rare diseases.” In terms of “Regulatory Operations in Rare Diseases,” the first graph highlights an overview of “Rare Disease.” The proportion of patients is small in terms of “rare diseases”. Revenues from orphan pharmaceuticals reached 132 billion dollars in 2020 [17]. Rare diseases or disorders defined in the US as affecting fewer than 200,000 patients are the focus of orphan



medications [17]. Though the number of approved orphan drugs rose from 364 in 2013 to 487 in 2017, the share of total spending attributed to orphan indication use rose from 8.1% to 9.6%, from about 3% in 1993 [18].

C. Case Study Outcomes

Case study	Company	Case study outcome	Relevance to current research
Zolgensma for SMA - Spinal Muscular Atrophy	Novartis	As per the case study, the company Novartis launched Zolgensma as a first-generation treatment for SMA. This has been identified as its one-time cure facility over chronic diagnosis, such as Spinraza.	This example has strengthened the contribution of the leader in the domain of "gene therapy." This shows how an effective regulatory initiative and medical information could demolish challenges,

		Authoritative acceptance related to the therapy refers to a transformation under the cure model of rare disease [12].	however, criticism over the pricing shows the need for more cost-effective options.
Pabinafusp -Alfa for Mucopolysaccharidoses Type II in Brazil	JCR Pharmaceuticals	As per the case, the drug was made reachable in regions like Brazil before its entire regulatory acknowledgment. This has highlighted the effectiveness of suppressing barriers related	Example of JCR Pharmaceuticals highlights the contribution of initial access programs that improve outcomes and experience of the patients while decreasing their



		to the “blood-brain” [13].	charges . This also increased the significance of advocacy communities for the patients in authoritative pathways to cure rare diseases.
Deflazacort for Duchenne Muscular Dystrophy	Marathon Pharmaceuticals	Apart from the approval from the FDA, the company observed criticism over its pricing and then sold Emflaza to PTC Therapeutics	This case study example highlights ethics around pricing in the approvals of “orphan drugs”, showing how achievement around regulati

		[14].	ons can be neglected by both political and public pressure over cost effectiveness.
--	--	-------	---

Table 1: Case Study Analysis

[Source: Self-Created]

Case study examples, in the above table, have highlighted how the pharmaceutical sector refers to authoritative operations, pricing initiatives and threats related to access to patients in terms of the rare disease cure programs.

D. Comparative Analysis

<i>Authors</i>	<i>Focus Area</i>	<i>Key Findings</i>	<i>Limitations</i>
[5]	Global Regulatory Pathways	The US Orphan Drug Act set a global precedent	Regulatory differences and unequal patient access.
[6]	Patient-Focused Drug Development (PFDD)	PFDD integrates patient input into drug approval, which is supported by the	Standardisation issues and potential patient bias.



		FDA and EMA	
[7]	Challenges in Orphan Drug Submissions	The Orphan Drug Act spurred development	Expensive drugs, limited industry incentives.
[8]	Regulatory Challenges & Cost Barriers	Regulations boost research but raise drug costs	Funding gaps and weak commercial interest.
[9]	Optimizing Regulatory Submissions	Faster market access via pricing strategies and regulatory efficiency.	Inconsistent regulations and funding issues.
[10]	Real-World Evidence	RWE supplements trials	Data variability and integration challenges.

Table 2: Comparative Analysis

[Source: Self-Created]

Table 2 highlights the comparative analysis of different authors, which is based on the study of regulatory operations in rare diseases. Different authors discussed the

regulatory challenges such as cost barriers, implementation barriers and many more. The regulatory agencies such as the FDA and EMA, standardised the submission in different countries. The discussion is also based on the global regulatory pathways that are the US Orphan Drug Act.

V. DISCUSSION

A. Interpretation of Results

The results align well with the objectives of the study by talking the contests of rare disease behaviours. The examination of global regulatory pathways, such as the US “Orphan Drug Act”, matches the objective of exploring available regulatory routes. Real-world side applications in regulatory operations, such as in the academic cases of Zolgensma and Pabinafusp-Alfa, appear rather and analyse their potential towards the optimisation of submissions of products in the market access [12]. Also, the comparison indicates that patient-centric development and with an adaptive regulatory approach and faster global approval. The proposed strategies and objectives are validated by these findings.

B. Practical Implications

The practical implication of this study is tremendous for regulatory bodies and pharmaceutical companies. Knowing how complex things are in rare disease drug submissions will allow companies to design more efficient clinical trial and submission strategies [19]. Whereas regulatory agencies can enhance their frameworks to better address the special circumstances of rare disease, namely limited patient population and the requirement for innovative data collection, such as real-world evidence (RWE). In addition, the case studies mentioned that early access programs and pricing are ways to address patient needs while putting cost control in check [19]. This information can facilitate policy choices, help the industry standardise, and lead the



developments in drug development and accessibility.

C. Challenges and Limitations

Several challenges remain concerning promising strategies. The cost of drug development is high, and it is particularly difficult for rare diseases because of their small patient population [20]. When there are not enough patients to recruit for clinical trials, it can be difficult to meet the requirements of regulatory agencies for an incredible amount of clinical trial data. There is also a lack of harmonised global regulatory standards, which makes it difficult for the pharmaceutical companies to gear different approval processes across different regions. Other limitations relate to the possibility of a bias in some main and effective features like “patient-focused drug development (PFDD)” and data variability in real world evidence, which may make it difficult for approval. The tremendous need for orphan drug development is not accompanied by standardised practices across the markets, which remains a barrier to the timely and cost-efficient development of orphan drugs.

D. Recommendations

Thus, to overcome these challenges, the regulatory bodies must develop more flexible and harmonised approaches to the submission of these drugs in rare diseases, which would be more flexible in terms of adaptive trial designs and greater use of RWE. Regulators are a natural partner for companies as they share common goals in achieving progress as fast as possible while achieving the highest quality of regulatory filings. Moreover, international collaboration towards regulatory standards will help the approval process, reduce redundancy, and reduce cost. From a patient access point of view, it is necessary to implement value-based pricing strategies and increase involvement of patient advocacy groups to resolve affordability concerns [21]. Lastly,

drug development can be administered such that therapies meet patient needs well if patient input is integrated into development.

VI. CONCLUSION AND FUTURE WORK

The regulatory operations in rare diseases have multiple challenges that can be mitigated through the help of different strategies. The challenges include a limited patient population, high implementation cost, and many more. Through the help of different regulatory bodies such as the FDA and EMA, this can be mitigated. Different authors address and identify the challenges and market access related to regulatory operations in rare diseases.

The future work of the study will consist of a brief description related to the international regulatory bodies such as the FDA and EMA. The current research lacks the in-depth concept of FDA and EMA, which will be included in the future research study for better understanding.

VII. REFERENCES

- [1] Mulberg, A.E., Bucci-Rechtweg, C., Giuliano, J., Jacoby, D., Johnson, F.K., Liu, Q., Marsden, D., McGoohan, S., Nelson, R., Patel, N. and Romero, K., 2019. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders. *Orphanet Journal of Rare Diseases*, 14, pp.1-10.
- [2] Czech, M., Baran-Kooiker, A., Atikeler, K., Demirtshyan, M., Gaitova, K., Holownia-Voloskova, M., Turcu-Stiolica, A., Kooiker, C., Piniazko, O., Konstandyan, N. and Zalis'ka, O., 2020. A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. *Frontiers in public health*, 7, p.416.
- [3] Lanar, S., Acquadro, C., Seaton, J., Savre, I. and Arnould, B., 2020. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare



diseases. *Orphanet Journal of Rare Diseases*, 15(1), p.134.

[4] Khosla, N. and Valdez, R., 2018. A compilation of national plans, policies and government actions for rare diseases in 23 countries. *Intractable & Rare Diseases Research*, 7(4), pp.213-222.

[5] Dharssi, S., Wong-Rieger, D., Harold, M. and Terry, S., 2017. Review of 11 national policies for rare diseases in the context of key patient needs. *Orphanet journal of rare diseases*, 12, pp.1

[6] Crossnohere, N.L., Fischer, R., Crossley, E., Vroom, E. and Bridges, J.F., 2020. The evolution of patient-focused drug development and Duchenne muscular dystrophy. Expert review of pharmacoeconomics & outcomes research, 20(1), pp.57-68.

[7] Rana, P. and Chawla, S., 2018. Orphan drugs: trends and issues in drug development. *Journal of basic and clinical physiology and pharmacology*, 29(5), pp.437-446.

[8] Davies, E.H., Fulton, E., Brook, D. and Hughes, D.A., 2017. Affordable orphan drugs: a role for not-for-profit organizations. *British journal of clinical pharmacology*, 83(7), pp.1595-1601.

[9] Lucas, F., 2018. Improving market access to rare disease therapies: a worldwide perspective with recommendations to the industry. *Medicine Access@ Point of Care*, 2, p.2399202618810121.

[10] Rath, A., Salamon, V., Peixoto, S., Hivert, V., Laville, M., Segrestin, B., Neugebauer, E.A., Eikermann, M., Bertele, V., Garattini, S. and Wetterslev, J., 2017. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?. *Trials*, 18, pp.1-11.

[11] Asenahabi, B.M., 2019. Basics of research design: A guide to selecting appropriate research design. *International*

Journal of Contemporary Applied Researches, 6(5), pp.76-89.

[12] Novartis.com, 2020. *Overview of the Company*, Available at: <https://www.novartis.com/about/novartis-gene-therapies> (Accessed on: 12th March 2020).

[13] Businesswire.com, 2020. *JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders*, Available at: (Accessed on: 20 January 2020).

[14] Fda.gov, 2017. *FDA approves drug to treat Duchenne muscular dystrophy*, Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-duchenne-muscular-dystrophy#:~:text=For%20Immediate%20Release:%20February%2009,age%20and%20worsen%20over%20time>. (Accessed on: 25 March 2017).

[15] Dawkins, H.J., Draghia-Akli, R., Lasko, P., Lau, L.P., Jonker, A.H., Cutillo, C.M., Rath, A., Boycott, K.M., Baynam, G., Lochmüller, H. and Kaufmann, P., 2017. Progress in rare diseases research 2010–2016: an IRDiRC perspective. *Clinical and translational science*, 11(1), p.11.

[16] Frontiersin.org, 2020, *pharmacology* Available at: <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.964426/full> (Accessed on: 21st February 2020)

[17] Statista.com, 2020, *projection-of-global-orphan-prescription* Available at: <https://www.statista.com/statistics/373326/projection-of-global-orphan-prescription-drug-revenues/> (Accessed on: 13th March 2020)

[18] Iqvia.com, 2020, *orphan-drugs* Available at: <https://www.iqvia.com/insights/the-iqvia-institute/reports-and->



publications/reports/orphan-drugs-in-the-united-states-growth-trends-in-rare-disease-treatments (Accessed on: 20 March 2020)

[19] Coppens, D.G.M., De Wilde, S., Guchelaar, H.J., De Bruin, M.L., Leufkens, H.G.M., Meij, P. and Hoekman, J., 2018. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. *Cytotherapy*, 20(6), pp.769-778.

[20] Mak, K.K. and Pichika, M.R., 2019. Artificial intelligence in drug development: present status and future prospects. *Drug discovery today*, 24(3), pp.773-780.

[21] Chintale, P. (2020). Designing a secure self-onboarding system for internet

customers using Google cloud SaaS framework. *IJAR*, 6(5), 482-487.

[22] Crossnohere, N.L., Fischer, R., Crossley, E., Vroom, E. and Bridges, J.F., 2020. The evolution of patient-focused drug development and Duchenne muscular dystrophy. *Expert review of pharmacoeconomics & outcomes research*, 20(1), pp.57-68

[23] "Balancing Privacy and Utility: Anonymisation Techniques for E-commerce Logistics Data", *int. J. Eng. Res. Sci. Tech.*, vol. 17, no. 2, pp. 65–75, Apr. 2021, doi: [10.62643/](https://doi.org/10.62643/).

[24] "Intelligent Process Automation in S/4 HANA FICO: A Machine Learning Approach", *IJIEE*, vol. 10, no. 2, pp. 57–70, Feb. 2020, doi: [10.48047/aqtbk646](https://doi.org/10.48047/aqtbk646).